Addiction

BrainsWay Vice President of Medical Affairs Colleen Hanlon Honored with the 2023 International Brain Stimulation Early Career Award

BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

2 years ago

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds…

2 years ago

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

Clearmind Medicine submitted patent applications to protect the novel compoundsTel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd.…

2 years ago

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

Type C meeting with FDA set for Second Quarter Plans in Place to Meet with Multiple Regulatory Agencies Throughout Europe…

2 years ago

Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY

OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects Study consistent with prior results…

2 years ago

BrainsWay Announces Appointment of Hadar Levy as CEO

BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

2 years ago

BrainsWay Announces Appointment of Ami Boehm as New Chairman

David Zacut, M.D., Relinquishing Chairman Role Held Since Company’s Inception, to Now Serve as Board DirectorBURLINGTON, Mass. and JERUSALEM, Feb.…

2 years ago

Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies

Immunocompromised Individuals, Including Organ Transplant Recipients, Are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes SARS-CoV-2 has Mutated…

2 years ago

Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

Topline Data Expected in 2Q 2023SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,…

2 years ago

Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the…

2 years ago